27 September 2023

PureTech Health plc

PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the appointment of Robert Lyne as Chief Portfolio Officer. Robert brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience.  Robert is expected to join PureTech by early January 2024.

"We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients," said Daphne Zohar, Founder and Chief Executive Officer of PureTech. "His extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech's own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties."

Mr. Lyne joins PureTech from Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as General Counsel and Chief Operating Officer before being appointed Chief Executive Officer in April 2021. He began his career as a lawyer at international law firm Bird & Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. He has worked on over 80 venture capital financings in Europe and North America as well as multiple trade exits and IPOs. As an experienced UK plc executive, Mr. Lyne has broad experience formulating and implementing corporate strategy. Mr. Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University.

"I am delighted to be joining the management team at PureTech during such an exciting time in the Company's growth," said Mr. Lyne. "As pioneers of the hub-and-spoke model in the biotechnology sector, PureTech's approach is aligned with my own experience and ambitions. They are highly innovative in their approach to both science and business, which has led to the team delivering an impressive track record of developing new therapies with transformational potential. I look forward to working with the skilled team at PureTech and its outstanding network of advisors to further drive the Company forward."

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to our expectations around our product candidates and approach towards addressing major diseases, and our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

PureTech

Public Relations

[email protected]

Investor Relations

[email protected]

EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

[email protected]

U.S. Media

Nichole Sarkis

+1 774 278 8273

[email protected]